Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Anderson

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
Science Immunology|July 20, 2022
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNsPaul Bastard, Sara E Vazquez, Jamin Liu, et al.
Nature|November 8, 2023
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiencyTom Le Voyer, Audrey V Parent, Xian Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
Science Immunology|July 20, 2022
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNsPaul Bastard, Sara E Vazquez, Jamin Liu, et al.
Nature|November 8, 2023
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiencyTom Le Voyer, Audrey V Parent, Xian Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 20